The role of Suppressors of Cytokine Signaling (SOCS) proteins in regulation of the immune response

Annual Review of Immunology

Volumn 22, Issue , 2004, Pages 503-529

  Alexander, Warren S ^a   Hilton, Douglas J ^a  

^a Department of Civil and Environmental Engineering   (Australia)

Author keywords

Attenuation; Cytokines; Negative regulation; Signal transduction; SOCS proteins

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; GAMMA INTERFERON; GROWTH HORMONE; HYBRID PROTEIN; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDE; PROTEIN SH2; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL SURFACE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CROHN DISEASE; DISEASE COURSE; DNA MODIFICATION; GENE DELETION; GENE TARGETING; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATORY DISEASE; MACROPHAGE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SKIN ALLERGY; STATISTICAL SIGNIFICANCE; SUPPRESSOR CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; CARRIER PROTEINS; CYTOKINES; HUMANS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 2542478996     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.091003.090312     Document Type: Review

References (146)

1. Nicola NA. 1994. An introduction to the cytokines. In Guidebook to Cytokines and Their Receptors, ed. NA Nicola. New York: Oxford Univ. Press
2. Hilton DJ. 1994. An introduction to cytokine receptors. In Guidebook to Cytokines and Their Receptors, ed. NA Nicola. New York: Oxford Univ. Press
3. Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, et al. 2001. Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13:363-73
4. Bazan JF. 1990. Haemopoietic receptors and helical cytokines. Immunol. Today. 11:350-54
5. Ihle JN, Kerr IM. 1995. Jaks and Stats in signalling by the cytokine receptor superfamily. Trends Genet. 11:69-74
6. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-21
7. Darnell JE Jr. 1997. STATs and gene regulation. Science 277:1630-35
8. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, et al. 1995. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:2816-26
9. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, et al. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-21
10. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-24
11. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-29
12. Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, et al. 1997. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun. 237:79-83
13. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, et al. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95:114-19
14. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. 2002. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27:235-41
15. Jegalian AG, Wu H. 2002. Regulation of Socs gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin. J. Biol. Chem. 277:2345-52
16. Gregorieff A, Pyronnet S, Sonenberg N, Veillette A. 2000. Regulation of SOCS-1 expression by translational repression. J. Biol. Chem. 275:21596-604
17. Schluter G, Boinska D, Nieman-Seyde SC. 2000. Evidence for translational repression of the SOCS-1 major open reading frame by an upstream open reading frame. Biochem. Biophys. Res. Commun. 268:255-61
18. He B, You L, Uematsu K, Matsangou M, Xu Z, et al. 2003. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem. Biophys. Res. Commun. 301:386-91
19. Donnelly RP, Dickensheets H, Finbloom DS. 1999. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 19:563-73
20. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, et al. 2001. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 97:1056-62
21. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, et al. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89:3148-54
22. Verdier F, Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, et al. 1998. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol. Cell Biol. 18:5852-60
23. Davey HW, McLachlan MJ, Wilkins RJ, Hilton DJ, Adams TE. 1999. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol. Cell Endocrinol. 158:111-16
24. Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, et al. 1997. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90:1768-76
25. Lee CK, Raz R, Gimeno R, Gertner R, Wistinghausen B, et al. 2002. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17:63-72
26. Stoiber D, Stockinger S, Steinlein P, Kovarik J, Decker T. 2001. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. J. Immunol. 166:466-72
27. Gautron L, Lafon P, Tramu G, Laye S. 2003. In vivo activation of the interleukin-6 receptor/gp130 signaling pathway in pituitary corticotropes of lipopolysaccharide-treated rats. Neuroendocrinology 77:32-43
28. Crespo A, Filla MB, Russell SW, Murphy WJ. 2000. Indirect induction of suppressor of cytokine signalling-1 in macrophages stimulated with bacterial lipopolysaccharide: partial role of autocrine/paracrine interferon-alpha/beta. Biochem. J. 349:99-104
29. Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. 1999. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J. Immunol. 163:2640-47
30. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, et al. 2002. SOCS-1 participates in negative regulation of LPS responses. Immunity 17:677-87
31. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, et al. 2002. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17:583-91
32. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, et al. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-20
33. Sporri B, Kovanen PE, Sasaki A, Yoshimura A, Leonard WJ. 2001. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 97:221-26
34. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, et al. 1999. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18:375-85
35. Fairlie WD, De Souza D, Nicola NA, Baca M. 2003. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2. Biochem. J. 372:495-502
36. De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M. 2002. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41:9229-36
37. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, et al. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97:6493-98
38. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. 2000. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:12848-56
39. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, et al. 2003. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 278:661-71
40. Friederichs K, Schmitz J, Weissenbach M, Heinrich PC, Schaper F. 2001. Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited. Eur. J. Biochem. 268:6401-7
41. Bjorbak C, Lavery HJ, Bates SH, Olson RK, Davis SM, et al. 2000. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275:40649-57
42. Eyckerman S, Broekaert D, Verhee A, Vandekerckhove J, Tavernier J. 2000. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486:33-37
43. Hermans MH, van de Geijn GJ, Antonissen C, Gits J, van Leeuwen D, et al. 2003. Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells. Blood 101:2584-90
44. Hortner M, Nielsch U, Mayr LM, Johnston JA, Heinrich PC, Haan S. 2002. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J. Immunol. 169:1219-27
45. Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13:1832-43
46. Ram PA, Waxman DJ. 1999. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274:35553-61
47. Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. 2002. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur. J. Biochem. 269:2516-26
48. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. 2000. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275:29338-47
49. Cohney SJ, Sanden D, Cacalano NA, Yoshimura A, Mui A, et al. 1999. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell Biol. 19:4980-88
50. Lejeune D, Demoulin JB, Renauld JC. 2001. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling. Biochem. J. 353:109-16
51. Losman J, Chen XP, Jiang H, Pan PY, Kashiwada M, et al. 1999. IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex. Cold Spring Harbor Symp. Quant. Biol. 64:405-16
52. Eyckerman S, Verhee A, der Heyden JV, Lemmens I, Ostade XV, et al. 2001. Design and application of a cytokine-receptor-based interaction trap. Nat. Cell Biol. 3:1114-19
53. Dif F, Saunier E, Demeneix B, Kelly PA, Edery M. 2001. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor. Endocrinology 142:5286-93
54. Aman MJ, Migone T-S, Sasaki A, Ascherman DP, Zhu M, et al. 1999. CIS associates with the interleukin-2 receptor β chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. 274:30266-72
55. Pezet A, Favre H, Kelly PA, Edery M. 1999. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J. Biol. Chem. 274:24497-502
56. Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, et al. 2002. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277:40181-14
57. Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, et al. 1998. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. USA 95:13130-34
58. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, et al. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96:2071-76
59. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, et al. 1998. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-81
60. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. 2002. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell Biol. 22:3316-26
61. Monni R, Santos SC, Mauchauffe M, Berger R, Ghysdael J, et al. 2001. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. Oncogene 20:849-58
62. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, et al. 2001. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276:12530-38
63. Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, et al. 2001. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. USA 98:13261-65
64. Alexander WS. 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2:410-16
65. Krebs DL, Hilton DJ. 2001. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19:378-87
66. Yoshimura A. 1998. The CIS/JAB family: novel negative regulators of JAK signaling pathways. Leukemia 12:1851-57
67. Naka T, Matsumoto T, Narazaki M, Fujimoto M, Morita Y, et al. 1998. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. USA 95:15577-82
68. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, et al. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95:14395-99
69. Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, et al. 2001. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193:263-69
70. Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamaria M, et al. 2001. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev. 15:1631-36
71. Cornish AL, Davey GM, Metcalf D, Purton JF, Corbin JE, et al. 2003. Suppressor of cytokine signaling-1 has IFN-gamma-independent actions in T cell homeostasis. J. Immunol. 170:878-86
72. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, et al. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98:609-16
73. Gresser I, Tovey MG, Maury C, Chouroulinkov I. 1975. Lethality of interferon preparations for newborn mice. Nature 258:76-78
74. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608
75. Metcalf D, Di Rago L, Mifsud S, Hartley L, Alexander WS. 2000. The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-gamma and lacking the SOCS-1 gene. Proc. Natl. Acad. Sci. USA 97:9174-79
76. Metcalf D, Alexander WS, Elefanty AG, Nicola NA, Hilton DJ, et al. 1999. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13:926-34
77. Brysha M, Zhang JG, Bertolino P, Corbin JE, Alexander WS, et al. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J. Biol. Chem. 276:22086-89
78. Grawunder U, Melchers F, Rolink A. 1993. Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur. J. Immunol. 23:544-51
79. Matsuda T, Yamamoto T, Kishi H, Yoshimura A, Muraguchi A. 2000. SOCS-1 can suppress CD3zeta- and Syk-mediated NF-AT activation in a non-lymphoid cell line. FEBS Lett. 472:235-40
80. Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, et al. 2001. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity 14:535-45
81. Eyles JL, Metcalf D, Grusby MJ, Hilton DJ, Starr R. 2002. Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J. Biol. Chem. 277:43735-40
82. Chong MM, Thomas HE, Kay TW. 2002. Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic beta cells to tumor necrosis factor. J. Biol. Chem. 277:27945-52
83. Morita Y, Naka T, Kawazoe Y, Fujimoto M, Narazaki M, et al. 2000. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc. Natl. Acad. Sci. USA 97:5405-10
84. + T cell differentiation. Immunity 18:475-87
85. -/- bone marrow cells into irradiated adult syngeneic recipients. Proc. Natl. Acad. Sci. USA 100:8436-41
86. Trop S, De Sepulveda P, Zuniga-Pflucker JC, Rottapel R. 2001. Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes. Blood 97:2269-77
87. Fujimoto M, Naka T, Nakagawa R, Kawazoe Y, Morita Y, et al. 2000. Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice. J. Immunol. 165:1799-806
88. Jameson SC. 2002. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2:547-56
89. Cornish AL, Chong MM, Davey GM, Darwiche R, Nicola NA, et al. 2003. SOCS-1 regulates signaling in response to IL-2 and other gamma c-dependent cytokines in peripheral T cells. J. Biol. Chem. 278:22755-61
90. Losman JA, Chen XP, Hilton D, Rothman P. 1999. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J. Immunol. 162:3770-74
91. Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS. 2002. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl. Acad. Sci. USA 99:943-48
92. Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. 2002. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168:3181-87
93. Fujimoto M, Tsutsui H, Yumikura-Futatsugi S, Ueda H, Xingshou O, et al. 2002. A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo. Int. Immunol. 14:1343-50
94. Bullen DV, Baldwin TM, Curtis JM, Alexander WS, Handman E. 2003. Persistence of lesions in suppressor of cytokine signaling-1-deficient mice infected with Leishmania major. J. Immunol. 170:4267-72
95. Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, et al. 2000. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13:805-15
96. Marine JC, McKay C, Wang D, Topham DJ, Parganas E, et al. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98:617-27
97. Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, et al. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA 98:9324-29
98. Bischof P, Haenggeli L, Campana A. 1995. Effect of leukemia inhibitory factor on human cytotrophoblast differentiation along the invasive pathway. Am. J. Reprod. Immunol. 34:225-30
99. Takahashi Y, Carpino N, Cross JC, Torres M, Parganas E, Ihle JN. 2003. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22:372-84
100. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:540-45
101. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, et al. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol 4:551-56
102. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, et al. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4:546-50
103. Song MM, Shuai K. 1998. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J. Biol. Chem. 273:35056-62
104. Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, et al. 2002. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. USA 99:8043-47
105. Yu CR, Mahdi RM, Ebong S, Vistica BP, Gery I, Egwuagu CE. 2003. Suppressor of cytokine signaling 3 (SOCS3) regulates proliferation and activation of T-helper cells. J. Biol. Chem. 278:29752-59
106. Matsumoto A, Seki Y, Watanabe R, Hayashi K, Johnston JA, et al. 2003. A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. J. Exp. Med. 197:425-36
107. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, et al. 2002. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc. Natl. Acad. Sci. USA 99:13003-8
108. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, et al. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93:841-50
109. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, et al. 1999. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell Biol. 19:6396-407
110. Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, et al. 2000. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J. Exp. Med. 191:985-94
111. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, et al. 2000. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069-73
112. Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, et al. 2002. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol. Endocrinol. 16:1394-406
113. Favre H, Benhamou A, Finidori J, Kelly PA, Edery M. 1999. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453:63-66
114. Dalpke AH, Opper S, Zimmermann S, Heeg K. 2001. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166:7082-89
115. Bertholet S, Dickensheets HL, Sheikh F, Gam AA, Donnelly RP, Kenney RT. 2003. Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: a novel mechanism for intracellular parasite suppression of activation. Infect. Immun. 71:2095-101
116. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez AC, Mellado M. 1999. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13:1699-710
117. Mellado M, Rodriguez-Frade JM, Aragay A, del Real G, Martin AM, et al. 1998. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J. Immunol. 161:805-13
118. Soriano SF, Hernanz-Falcon P, Rodriguez-Frade JM, De Ana AM, Garzon R, et al. 2002. Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J. Exp. Med. 196:311-21
119. Ward AC, Touw I, Yoshimura A. 2000. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95:19-29
120. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, et al. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-12
121. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, et al. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:2535-40
122. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. 2001. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell Biol. 21:3547-57
123. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, et al. 2002. The tumor suppressor activity of SOCS-1. Oncogene 21:4351-62
124. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, Melo JV. 2002. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99:1766-75
125. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, et al. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29-35
126. Nagai H, Kim YS, Konishi N, Baba M, Kubota T, et al. 2002. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett. 186:59-65
127. Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, et al. 2003. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J. Hum. Genet. 48:65-69
128. Nagai H, Kim YS, Lee KT, Chu MY, Konishi N, et al. 2001. Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis. J. Hepatol. 34:416-21
129. Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, et al. 2003. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37:300-5
130. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784-88
131. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. 2002. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100:2926-31
132. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, et al. 2001. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193:471-81
133. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, et al. 2003. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J. Biol. Chem. 278:16777-81
134. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, et al. 2001. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108:1781-88
135. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. 2003. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Invest. 111:915-24
136. Seki YI, Inoue H, Nagata N, Hayashi K, Fukuyama S, et al. 2003. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat. Med. 9:1047-54
137. Federici M, Giustizieri ML, Scarponi C, Girolomoni G, Albanesi C. 2002. Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J. Immunol. 169:434-42
138. Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, et al. 2002. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol. Cell Biol. 22:4567-78
139. Jones SA, Rose-John S. 2002. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim. Biophys. Acta 1592:251-63
140. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. 1996. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 16:6985-92
141. Ihle JN, Witthuhn BA, Quelle FW, Silvennoinen O, Tang B, Yi T. 1994. Protein tyrosine phosphorylation in the regulation of hematopoiesis by receptors of the cytokine-receptor superfamily. Blood Cells 20:65-80, discussion 2
142. Qu CK. 2002. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim. Biophys. Acta 1592:297-301
143. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, et al. 2001. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409:349-54
144. Yamada T, Zhu D, Saxon A, Zhang K. 2002. CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase. J. Biol. Chem. 277:28830-35
145. Yamamoto T, Sekine Y, Kashima K, Kubota A, Sato N, et al. 2002. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem. Biophys. Res. Commun. 297:811-17
146. Aoki N, Matsuda T. 2002. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol. Endocrinol. 16:58-69